A Study to Identify and Characterize LAL-D Patients in High-risk Populations

A Study to Identify the Frequency of Lysosomal Acid Lipase Deficiency in At-Risk Patient Populations

Status

Terminated

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT02345421

Enrollment

640

Registered

2015-01-26

Start date

2014-12-31

Completion date

2015-10-31

Last updated

2016-05-24

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Lysosomal Acid Lipase Deficiency

Keywords

LAL D, CESD, NASH, NAFLD, Wilson's, Niemann Pick, Familial Hypercholesterolemia

Brief summary

The objective of this study is to determine the frequency of Lysosomal Acid Lipase Deficiency (LAL D) by lysosomal acid lipase (LAL) enzyme activity assay in patients who are considered to be at risk.

Interventions

None listed

Study design

Observational model

CASE_ONLY

Eligibility

Sex/Gender

ALL

Age

2 Years to No maximum

Healthy volunteers

Inclusion criteria

1. Non-obese\*\* patients with elevated low-density lipoprotein (LDL) 2. Non-obese\*\* patients with low high-density lipoprotein (HDL) 3. Non-obese\*\* patients with unexplained and persistently elevated liver transaminases, 4. Non-obese\*\* patients with hepatomegaly 5. Patients with cryptogenic cirrhosis 6. Patients with biopsy-proven microvesicular or mixed micro/macrovesicular steatosis without a known etiology 7. Patients with presumed Familial Hypercholesterolemia (FH) in which genetic analysis was performed for the genes encoding the low-density lipoprotein receptor (LDLR), Apo-B and PCSK9 genes and no disease-causing mutations were identified 8. Patients with presumed FH with unclear family history 9. Patients with autosomal recessive hypercholesterolemia (other than homozygous FH) 10. Patients with autosomal recessive low HDL of unknown etiology Also, patient must meet the following: * Patient or patient's parent or legal guardian (if applicable) consents to participate in the study and provides informed consent prior to any study procedures being performed. If the patient is of minor age; he/she is willing to provide assent where required per local regulations, and if deemed able to do so. * Patient is willing and able to comply with protocol requirements. * Patients who do not fall into one of the aforementioned categories (cohorts) but are considered highly suspicious for LAL D should be tested to rule out the disorder outside of the study at the discretion of the Investigator.

Exclusion criteria

* Active viral hepatitis; * Other confirmed genetic liver diseases (e.g., Wilson's disease, hemochromatosis, alpha 1-antitrypsin).

Design outcomes

Primary

Measure	Time frame	Description
LAL D frequency based on LAL enzyme assay.	approximately 1 month	The endpoint of this study is the frequency of LAL D in at-risk patients, based on results from the LAL enzyme assay.

Countries

United States

Outcome results